Tainwala Chem. (TAINWALCHM)
Score breakdown: P/E: 2/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1
Key Financials
| Current Price | ₹205.78 |
| Market Cap | ₹192.69 Cr |
| P/E Ratio | 24.1 |
| ROCE | 4.24% |
| ROE | 6.92% |
| Dividend Yield | 1.46% |
| Profit Growth | -98.93% |
| Debt/Equity | 0 |
| Sales Growth | -76.81% |
| Free Cash Flow | ₹1.11 Cr |
| Promoter Holding | 67.51% |
| 52-Week Range | ₹155 — ₹258.7 |
| Sector | Industrial Products |
| Book Value | ₹183.88 |
AI Analysis
AI-generated, general educational analysis — not personal investment advice.
At first glance, Tainwala Chem looks like a stock in recovery. Sales grew 43% and profit exploded over 1,100%, but I have learned to be suspicious of numbers that look too good. A 1,116% profit gain usually means the base was very low, not that a durable franchise has appeared. Latest quarter shows ₹10 Cr sales and ₹3 Cr net profit, which is a fine margin, yet free cash flow is only ₹1 Cr. Profits without cash are not profits I can trust. The balance sheet is clean: zero debt is always a plus, and 67.51% promoter holding means owners are still on board. Piotroski score of 7 out of 9 also suggests some fundamental improvement. But let's keep this in perspective. Return on equity is just 6.92%, and return on capital employed is only 4.24%. That is not what I call a wonderful business. Plastic industrial products likely lack pricing power and a durable moat. I cannot ignore Altman Z-Score of 1.78. Even with no debt, the score sits in the caution/distress zone. That forces me to check whether earnings quality is real. Now valuation: The Graham Number is ₹204.46, just above the price, so the stock is trading at a tiny negative margin of safety of -2.31%. But my DCF estimate, using visible cash generation, gives ₹63.49 per share. That is a massive gap. P/E of 18.42 for a business earning 6.92% ROE is not cheap, and EV/EBITDA of 9.72 is not distressed pricing. The PEG of 0.55 is an illusion created by a low-base earnings jump. So what is this? Maybe a turnaround, perhaps a cyclical recovery, but not a predictable compounder. I prefer paying a fair price for a wonderful company, not a questionable price for an average one. I will watch from the sidelines unless consistent cash flow and better returns on capital appear.
The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer